Brygida Bisikirska

Brygida Bisikirska

Auto-generated profile, based on publicly available information

Brygida Bisikirska

Department of Physiology and Cellular Biophysics, Columbia University Medical Center, New York, NY 10032, USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 January 2022 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
MGMarta Galán-Díez
Marta Galán-Díez
FBFlorence Borot
Florence Borot
AAAbdullah Mahmood Ali
Abdullah Mahmood Ali
JZJunfei Zhao
Junfei Zhao
EGEva Gil-Iturbe
Eva Gil-Iturbe
SKStavroula Kousteni
Stavroula Kousteni
Remodeling of the microenvironment by tumor cells can activate pathways that favor cancer growth. Molecular delineation and targeting of such malignant-cell nonautonomous pathways may help overcome resistance to targeted therapies. Herein we leverage genetic mouse models, patient-derived xenografts, and patient samples to show that acute myeloid leukemia (AML) exploits peripheral serotonin signaling to remodel the endosteal niche to its advantage. AML progression requires the presence of serotonin receptor 1B (HTR1B) in osteoblasts and is driven by AML-secreted kynurenine, which acts as an oncometabolite and HTR1B ligand. AML cells utilize kynurenine to induce a proinflammatory state in osteoblasts that, through the acute-phase protein serum amyloid A (SAA), acts in a positive feedback loop on leukemia cells by increasing expression of IDO1—the rate-limiting enzyme for kynurenine synthesis—thereby enabling AML progression. This leukemia–osteoblast cross-talk, conferred by the kynurenine–HTR1B–SAA–IDO1 axis, could be exploited as a niche-focused therapeutic approach against AML, opening new avenues for cancer treatment. Significance: AML remains recalcitrant to treatments due to the emergence of resistant clones. We show a leukemia-cell nonautonomous progression mechanism that involves activation of a kynurenine–HTR1B–SAA–IDO1 axis between AML cells and osteoblasts. Targeting the niche by interrupting this axis can be pharmacologically harnessed to hamper AML progression and overcome therapy resistance. This article is highlighted in the In This Issue feature, p. 873

16 October 2024 in Science Translational Medicine
Verified
Journal Article
Closed access
BBBrygida Bisikirska
Brygida Bisikirska
RLRossella Labella
Rossella Labella
ACAlvaro Cuesta-Dominguez
Alvaro Cuesta-Dominguez
NLNa Luo
Na Luo
JAJessica De Angelis
Jessica De Angelis
SKStavroula Kousteni
Stavroula Kousteni
Idiopathic osteoporosis (IOP) is a rare form of early-onset osteoporosis diagnosed in patients with no known metabolic or hormonal cause of bone loss and unknown pathogenesis. Patients with IOP commonly report both childhood fractures and family history of osteoporosis, raising the possibility of genetic etiologies of IOP. Whole-exome sequencing analyses of different IOP cohorts identified multiple variants in melatonin receptor 1A ( MTNR1A ) with a potential pathogenic outcome. A rare MTNR1A variant (rs374152717) was found in members of an Ashkenazi Jewish family with IOP, and an MTNR1A variant (rs28383653) was found in a nonrelated female IOP cohort (4%). Both variants occur at a substantially higher frequency in Ashkenazi Jewish individuals than in the general population. We investigated consequences of the heterozygous (rs374152717) variant [ MTNR1A c.184+1G>T ( MTNR1A c. 184+1G>T )] on bone physiology. A mouse model of the human rs374152717 variant reproduced the low bone mass (BM) phenotype of young-adult patients with IOP. Low BM occurred because of induction of senescence in mutant osteoblasts followed by compromised differentiation and function. In human cells, introduction of rs374152717 led to translation of a nonfunctional protein and subsequent dysregulation of melatonin signaling. These studies provide evidence that MTNR1A mutations entail a genetic etiology of IOP and establish the rs374152717 variant as a loss-of-function allele that impairs bone turnover by inducing senescence in osteoblasts. The higher prevalence of the MTNR1A variants identified in IOP cohorts versus the general population indicates a greater risk of IOP in those carrying these variants, especially Ashkenazi Jewish individuals bearing the rs374152717 variant.

4 April 2023
Verified
Other
Open access
MGMarta Galán-Díez
Marta Galán-Díez
FBFlorence Borot
Florence Borot
AAAbdullah Mahmood Ali
Abdullah Mahmood Ali
JZJunfei Zhao
Junfei Zhao
EGEva Gil-Iturbe
Eva Gil-Iturbe
SKStavroula Kousteni
Stavroula Kousteni
Supplementary Figure from Subversion of Serotonin Receptor Signaling in Osteoblasts by Kynurenine Drives Acute Myeloid Leukemia

4 April 2023
Verified
Other
Open access
MGMarta Galán-Díez
Marta Galán-Díez
FBFlorence Borot
Florence Borot
AAAbdullah Mahmood Ali
Abdullah Mahmood Ali
JZJunfei Zhao
Junfei Zhao
EGEva Gil-Iturbe
Eva Gil-Iturbe
SKStavroula Kousteni
Stavroula Kousteni
Supplementary Figure from Subversion of Serotonin Receptor Signaling in Osteoblasts by Kynurenine Drives Acute Myeloid Leukemia

4 April 2023
Verified
Other
Open access
MGMarta Galán-Díez
Marta Galán-Díez
FBFlorence Borot
Florence Borot
AAAbdullah Mahmood Ali
Abdullah Mahmood Ali
JZJunfei Zhao
Junfei Zhao
EGEva Gil-Iturbe
Eva Gil-Iturbe
SKStavroula Kousteni
Stavroula Kousteni
Supplementary Figure from Subversion of Serotonin Receptor Signaling in Osteoblasts by Kynurenine Drives Acute Myeloid Leukemia

4 April 2023
Verified
Other
Open access
MGMarta Galán-Díez
Marta Galán-Díez
FBFlorence Borot
Florence Borot
AAAbdullah Mahmood Ali
Abdullah Mahmood Ali
JZJunfei Zhao
Junfei Zhao
EGEva Gil-Iturbe
Eva Gil-Iturbe
SKStavroula Kousteni
Stavroula Kousteni
Remodeling of the microenvironment by tumor cells can activate pathways that favor cancer growth. Molecular delineation and targeting of such malignant-cell nonautonomous pathways may help overcome resistance to targeted therapies. Herein we leverage genetic mouse models, patient-derived xenografts, and patient samples to show that acute myeloid leukemia (AML) exploits peripheral serotonin signaling to remodel the endosteal niche to its advantage. AML progression requires the presence of serotonin receptor 1B (HTR1B) in osteoblasts and is driven by AML-secreted kynurenine, which acts as an oncometabolite and HTR1B ligand. AML cells utilize kynurenine to induce a proinflammatory state in osteoblasts that, through the acute-phase protein serum amyloid A (SAA), acts in a positive feedback loop on leukemia cells by increasing expression of IDO1—the rate-limiting enzyme for kynurenine synthesis—thereby enabling AML progression. This leukemia–osteoblast cross-talk, conferred by the kynurenine–HTR1B–SAA–IDO1 axis, could be exploited as a niche-focused therapeutic approach against AML, opening new avenues for cancer treatment.Significance:AML remains recalcitrant to treatments due to the emergence of resistant clones. We show a leukemia-cell nonautonomous progression mechanism that involves activation of a kynurenine–HTR1B–SAA–IDO1 axis between AML cells and osteoblasts. Targeting the niche by interrupting this axis can be pharmacologically harnessed to hamper AML progression and overcome therapy resistance.This article is highlighted in the In This Issue feature, p. 873